跳至主要内容
临床试验/NL-OMON50622
NL-OMON50622招募中不适用

Determination of new biomarkers in patients with resectable colorectal liver metastases, the MIRACLE study - MIRACLE

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >= 18 years.
  • Histologically confirmed primary colorectal carcinoma.
  • Radiological confirmed and resectable liver metastasis of colorectal cancer,
  • planned to undergo resection with or without neo-adjuvant chemotherapy.
  • Before patient registration, written informed consent must be given according
  • to ICH/GCP, and national/local regulations.

排除标准

  • Prior adjuvant chemotherapy for the primary colorectal carcinoma given <6
  • months prior to detection of the liver metastases.
  • Prior non colorectal malignancies, except for patients with basal or squamous
  • cell carcinoma of the skin, or patients with carcinoma in situ of the cervix.
  • Presence of extrahepatic disease. Patients with small (<=1 cm) extrahepatic
  • lesions that are not clearly suspicious of metastases are eligible.
  • Females with a positive pregnancy test (within 14 days before treatment start).
  • History of psychiatric disability judged by the investigator to be clinically
  • significant, precluding informed consent.
  • Current or recent treatment with another investigational drug or participation
  • in another investigational study.
  • Any psychological, familial, sociological or geographical condition potentially
  • hampering compliance with the study protocol and follow-up schedule; those
  • conditions should be discussed with the patient before registration in study.

研究者

相似试验